453 related articles for article (PubMed ID: 16549597)
1. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.
Adhikary D; Behrends U; Moosmann A; Witter K; Bornkamm GW; Mautner J
J Exp Med; 2006 Apr; 203(4):995-1006. PubMed ID: 16549597
[TBL] [Abstract][Full Text] [Related]
2. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
3. Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus.
Delecluse HJ; Feederle R; Behrends U; Mautner J
Semin Cancer Biol; 2008 Dec; 18(6):409-15. PubMed ID: 18938248
[TBL] [Abstract][Full Text] [Related]
4. A11 Tetramer-assisted characterization of Rta-specific CD8+ T-cell responses in healthy virus carriers.
Yu HX; Srinivasan N; Ren EE; Chan SH
Tissue Antigens; 2005 Jun; 65(6):539-43. PubMed ID: 15896201
[TBL] [Abstract][Full Text] [Related]
5. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
Mautner J; Bornkamm GW
Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
[TBL] [Abstract][Full Text] [Related]
6. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.
Tan LC; Gudgeon N; Annels NE; Hansasuta P; O'Callaghan CA; Rowland-Jones S; McMichael AJ; Rickinson AB; Callan MF
J Immunol; 1999 Feb; 162(3):1827-35. PubMed ID: 9973448
[TBL] [Abstract][Full Text] [Related]
7. Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH; Brestrich G; Mittenzweig A; Roemhild A; Zwinger S; Subklewe M; Beier C; Kurtz A; Babel N; Volk HD; Reinke P
J Immunother; 2007; 30(8):817-24. PubMed ID: 18049333
[TBL] [Abstract][Full Text] [Related]
8. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.
Niller HH; Wolf H; Minarovits J
Autoimmunity; 2008 May; 41(4):298-328. PubMed ID: 18432410
[TBL] [Abstract][Full Text] [Related]
9. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
10. T-cell response to B-cells and Epstein-Barr virus antigens in infectious mononucleosis.
Klein E; Ernberg I; Masucci MG; Szigeti R; Wu YT; Masucci G; Svedmyr E
Cancer Res; 1981 Nov; 41(11 Pt 1):4210-5. PubMed ID: 6272964
[TBL] [Abstract][Full Text] [Related]
11. Frequency of CD8(+) T lymphocytes specific for lytic and latent antigens of Epstein-Barr virus in healthy virus carriers.
Benninger-Döring G; Pepperl S; Deml L; Modrow S; Wolf H; Jilg W
Virology; 1999 Nov; 264(2):289-97. PubMed ID: 10562493
[TBL] [Abstract][Full Text] [Related]
12. EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection.
van Gent M; Griffin BD; Berkhoff EG; van Leeuwen D; Boer IG; Buisson M; Hartgers FC; Burmeister WP; Wiertz EJ; Ressing ME
J Immunol; 2011 Feb; 186(3):1694-702. PubMed ID: 21191071
[TBL] [Abstract][Full Text] [Related]
13. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
[TBL] [Abstract][Full Text] [Related]
14. The human T cell immune response to Epstein-Barr virus.
Landais E; Saulquin X; Houssaint E
Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
[TBL] [Abstract][Full Text] [Related]
15. B-cell polyclonal activation and Epstein-Barr viral abortive lytic cycle are two key features in acute infectious mononucleosis.
Al Tabaa Y; Tuaillon E; Jeziorski E; Ouedraogo DE; Bolloré K; Rubbo PA; Foulongne V; Rodière M; Vendrell JP
J Clin Virol; 2011 Sep; 52(1):33-7. PubMed ID: 21684200
[TBL] [Abstract][Full Text] [Related]
16. Epstein-Barr virus infection of CR2-transfected epithelial cells reveals the presence of MHC class II on the virion.
Knox PG; Young LS
Virology; 1995 Oct; 213(1):147-57. PubMed ID: 7483258
[TBL] [Abstract][Full Text] [Related]
17. Differential targeting and shifts in the immunodominance of Epstein-Barr virus--specific CD8 and CD4 T cell responses during acute and persistent infection.
Woodberry T; Suscovich TJ; Henry LM; Davis JK; Frahm N; Walker BD; Scadden DT; Wang F; Brander C
J Infect Dis; 2005 Nov; 192(9):1513-24. PubMed ID: 16206065
[TBL] [Abstract][Full Text] [Related]
18. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time.
Iancu EM; Corthesy P; Baumgaertner P; Devevre E; Voelter V; Romero P; Speiser DE; Rufer N
J Immunol; 2009 Jul; 183(1):319-31. PubMed ID: 19542443
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M; Sebelin K; Block A; Meier A; Roukens A; Paludan C; Fonteneau JF; Steinman RM; Münz C
Hum Immunol; 2005 Sep; 66(9):938-49. PubMed ID: 16360833
[TBL] [Abstract][Full Text] [Related]
20. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
